The window for cognitive recovery after devastating brain trauma may be narrower than previously recognized, with treatment timing emerging as a critical determinant of outcomes. This insight challenges current rehabilitation protocols that often delay pharmacological intervention until patients are medically stable. A comprehensive analysis of severe traumatic brain injury cases reveals that neurostimulant medications, when administered strategically, can dramatically influence cognitive recovery trajectories. The investigation tracked 405 patients across eight major trauma centers, focusing on those with Glasgow Coma Scale scores of 8 or below—indicating profound unconsciousness. Nearly 30% received neurostimulants, primarily amantadine, with treatment typically beginning around day eight post-injury. Patients receiving these medications within the first week demonstrated threefold higher odds of achieving favorable cognitive outcomes compared to those treated later, despite initially presenting with more severe injuries and requiring more invasive neurosurgical procedures. The early intervention group achieved a 30.8% favorable outcome rate measured by Disability Rating Scale scores below 12. This timing-dependent effect suggests a critical neuroplasticity window during acute recovery phases when damaged neural networks retain maximum capacity for reorganization. The finding contradicts conventional approaches that prioritize medical stabilization over cognitive intervention. While amantadine has established neuroprotective properties through NMDA receptor antagonism and dopamine enhancement, this analysis provides the first robust evidence for optimal timing windows. However, the retrospective design limits causal interpretation, and the selection criteria for neurostimulant administration may have introduced unmeasured confounding factors that influenced outcomes beyond medication timing alone.